<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108833</url>
  </required_header>
  <id_info>
    <org_study_id>TASLY-B1448</org_study_id>
    <nct_id>NCT03108833</nct_id>
  </id_info>
  <brief_title>A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism</brief_title>
  <acronym>ERUPTE</acronym>
  <official_title>A Phase IIa Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tasly Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tasly Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is being conducted to assess the efficacy and safety of recombinant Human
      Prourokinase in the acute pulmonary embolism.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Qanadli CT Score</measure>
    <time_frame>0 and 48hours after treatment</time_frame>
    <description>Change of Qanadli Score from baseline by CTPA 48hours after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average pulmonary artery pressure</measure>
    <time_frame>0,24hours，48hours，7days and 30days after treatment</time_frame>
    <description>Changes of average pulmonary artery pressure from baseline 24hours，48hours，7days and 30days after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Three tricuspid regurgitation velocity</measure>
    <time_frame>0,24hours，48hours，7days and 30days after treatment</time_frame>
    <description>Changes of Three tricuspid regurgitation velocity from baseline 24hours，48hours，7days and 30days after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RV to LV Diameter Ratio</measure>
    <time_frame>0,24hours，48hours，7days and 30days after treatment</time_frame>
    <description>Changes of RV to LV Diameter Ratio from baseline 24hours，48hours，7days and 30days after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sPESI score</measure>
    <time_frame>0 and 7days after treatment</time_frame>
    <description>Changes of sPESI score from baseline 7days after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>0，48hours and 30days after treatment</time_frame>
    <description>Changes of NT-proBNP from baseline 48hours and 30days after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>From baseline to 30 days</time_frame>
    <description>The frequency of major bleeding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of death from all causes or hemodynamic shock</measure>
    <time_frame>From baseline to 7 days</time_frame>
    <description>Incidence of death from all causes or hemodynamic shock</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of recurrent pulmonary embolism fatal or non fatal</measure>
    <time_frame>From baseline to 7 days</time_frame>
    <description>Incidence of recurrent pulmonary embolism fatal or non fatal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of death from all causes</measure>
    <time_frame>From baseline to 30 days</time_frame>
    <description>Incidence of death from all causes</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Acute Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Low Dose Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant Human Prourokinase:40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant Human Prourokinase:50mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator Controlled Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alteplase:100mg if weight&gt;=65kg, 1.5mg/kg if weight&lt;65kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Prourokinase</intervention_name>
    <description>The drug is used for intravenous thrombolysis therapy</description>
    <arm_group_label>Low Dose Experimental Group</arm_group_label>
    <arm_group_label>High Dose Experimental Group</arm_group_label>
    <other_name>rhPro-UK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>The drug is used for intravenous thrombolysis therapy</description>
    <arm_group_label>Active Comparator Controlled Group</arm_group_label>
    <other_name>Actilyse</other_name>
    <other_name>rtPA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 30-70 years（Include the critical value）AND

          2. Massive PE or submassive PE AND

          3. PE symptom duration ≤14 days AND

          4. PLT≥100×10^9/L，ALT and AST≤2.5ULN，TBIL＜ULN，CrCL&gt;80mL/min AND

          5. Informed consent can be obtained from subject or Legally Authorized Representative

        Exclusion Criteria:

          1. Hemorrhagic or unexplained stroke history

          2. Ischemic stroke or transient ischemic attack (TIA) within 6 months

          3. The existence of the central nervous system injury or tumor

          4. Severe trauma，major surgery or head injury within 3 weeks

          5. Active bleeding within 1 month

          6. Clinician deems high-risk for bleeding

          7. Using anticoagulants (after a washout period can be randomized)

          8. Pregnancy or delivery within 1 week

          9. Vascular puncture which can not be oppressed

         10. Cardiopulmonary resuscitation within 10 days

         11. Systolic blood pressure above 180 mmHg or diastolic blood pressure above 100mmHg

         12. Severe liver dysfunction

         13. Infective endocarditis

         14. Arterial aneurysm or arteriovenous malformation or suspected aortic dissection

         15. left atrial thrombus

         16. Neurosurgery or eye surgery within 1 month

         17. Hemorrhagic diabetic retinopathy

         18. Serious cardiac insufficiency

         19. ventricular arrhythmias

         20. Known allergic to prourokinase，urokinase，recombinant tissue-type plasminogen
             activator，contrast agent or any drug in the trial

         21. Do not allow for 30 days' study

         22. Any disease or condition is not suitable for intravenous thrombolysis

         23. Lactating women or plan to pregnant women during the trial，or don't want to during the
             study period using effective contraception or abstinence of male and female patients
             with possibility of fertility

         24. Clinician thinks patient doesn't fit to participate in the test of other diseases or
             conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Min Zhao, PhD</last_name>
    <phone>022-86343656</phone>
    <email>zhaomin@tasly.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yong Zhang</last_name>
    <phone>02286343651</phone>
    <email>zhangyong3@tasly.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi-Cheng Jing, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhong Mi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Shijitan Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Pan, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tongren Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianqi Wang, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhancheng Gao, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bingxiang Wu, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuanyu Gao, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guozhong Chen, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Asia Heart Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongmei Zhou, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zaixin Yu, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hang Zhang, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeqi Zheng, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weihua Zhang, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dechun Su, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Kang, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fenling Fan, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Chest Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuechuan Li, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Haihe Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Wu, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital affiliated with the Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kejing Ying, M.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Saruplase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

